BioDelivery Sciences International Inc. (NASDAQ:BDSI) shares traded up 5.5% on Wednesday . The stock traded as high as $2.55 and last traded at $2.48, with a volume of 328,252 shares trading hands. The stock had previously closed at $2.35.

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a research note on Saturday, July 9th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $4.00 price target (down from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. FBR & Co upped their price target on shares of BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Wednesday, May 4th. Roth Capital reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a report on Monday, March 28th. Finally, Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Thursday, July 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $8.25.

The firm’s market cap is $132.91 million. The firm has a 50 day moving average price of $2.46 and a 200 day moving average price of $3.16.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. The company earned $3 million during the quarter, compared to analyst estimates of $2.96 million. During the same period last year, the company earned ($0.16) earnings per share. The firm’s revenue was down 77.1% compared to the same quarter last year. Equities analysts anticipate that BioDelivery Sciences International Inc. will post ($1.19) EPS for the current fiscal year.

Several hedge funds and institutional investors have added to or reduced their stakes in BDSI. Sei Investments Co. boosted its position in BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares in the last quarter. 1492 Capital Management LLC raised its stake in shares of BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock worth $2,580,000 after buying an additional 41,069 shares during the last quarter. Bank of Montreal Can raised its stake in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares during the last quarter. Turner Investments L.P. raised its stake in shares of BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 321,290 shares during the last quarter. Finally, Russell Frank Co raised its stake in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock worth $5,151,000 after buying an additional 394,272 shares during the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.